Inactive Instrument

Press Releases Albireo Pharma, Inc.

Equities

ALBO

US01345P1066

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

ALBIREO PHARMA, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	23-03-02	AQ
Albireo Pharma, Inc. - FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay in Alagille Syndrome	23-02-15	AQ
ALBIREO PHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-02-14	AQ
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome	23-02-14	AQ
ALBIREO PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Albireo Pharma, Inc. - ALBO	23-01-24	BU
ALBIREO PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Albireo Pharma, Inc. - ALBO	23-01-10	BU
Albireo Pharma : Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases - Form 8-K	23-01-09	PU
ALBIREO PHARMA, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-01-09	AQ
Albireo Pharma : Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases	23-01-09	PU
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	22-12-20	AQ
Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA	22-12-19	AQ
Albireo Appoints Paul Streck, M.D., as Chief Medical Officer and Craig Hopkinson, M.D., to Board of Directors	22-12-07	AQ
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	22-12-06	AQ
ALBIREO PHARMA, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22-12-06	AQ
Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors	22-12-06	AQ
Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 & 2	22-11-30	GL
Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 & 2	22-11-30	AQ
Albireo to Participate in Jefferies London Healthcare Conference	22-11-09	AQ
ALBIREO PHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-11-08	AQ
Albireo Reports Q3 2022 Financial Results and Business Update	22-11-08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Albireo Pharma, Inc.

Equities

ALBO

US01345P1066

Press Releases

Filters